Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04566666 · ClinicalTrials.gov registry record · Phase 2
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT04566666: Completed Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
NCT04566666 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 263 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04566666, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.
Primary Outcome
The subjects showing at least 75% improvement in Psoriasis Area and Severity Index score on a scale of 0-4 score. Higher score denotes more severe disease activity. The information presented represents the percentage of subjects, calculated as the proportion of subjects multiplied by 100.
Interventions
- DRUG Placebo
- DRUG SCD-044_Low Dose (Dose 1)
- DRUG SCD-044_Intermediate Dose (Dose 2)
- DRUG SCD-044_High Dose (Dose 3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2021-03-25 |
| Est. Completion | 2025-08-27 |
| Phase | Phase 2 |
What the finished NCT04566666 record still lists
NCT04566666 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04566666 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04566666 about?
NCT04566666 is a clinical study titled "To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis". This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT04566666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2021-03-25. Estimated completion is 2025-08-27.
What interventions are being tested in trial NCT04566666?
The interventions under investigation include: Placebo (DRUG), SCD-044_Low Dose (Dose 1) (DRUG), SCD-044_Intermediate Dose (Dose 2) (DRUG), SCD-044_High Dose (Dose 3) (DRUG).
Who is sponsoring clinical trial NCT04566666?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04566666's enrollment target sits among peer trials
263 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI